COMBINATION COMPOSITIONS FOR TREATING DISORDERS REQUIRING REMOVAL OR DESTRUCTION OF UNWANTED CELLULAR PROLIFERATIONS
The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors using compounds based on small peptides in combination with additional active agent(s). The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intraprostatically, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a mammal in need thereof.
1 . A method of treating a mammal for removal or destruction of unwanted cellular proliferations comprising administering to the mammal a therapeutically effective amount of an isolated peptide comprising the amino acid sequence in SEQ ID NO. 66 (Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-Lys-Leu-Glu-Ile-Lys-Arg-Cys-Leu), in combination with at least one active agent capable of treating symptoms of, reducing, blocking, inhibiting treating and/or killing unwanted cellular proliferations in mammals, wherein the method removes or destroys unwanted cellular proliferations.
2 . The method of claim 1 , wherein the method comprises administration of a therapeutically effective amount of at least one of the peptides as claimed in claim 1 and a carrier.
3 . The method of claim 1 , wherein the at least one active agent capable of treating symptoms of, reducing, blocking, inhibiting treating and/or killing unwanted cellular proliferations in mammals, is one or more agents selected from the group consisting of of tamsulosin, finasteride, terazosin, doxazosin, prazosin, tadalafil, alfuzosin, silodosin, dutasteride, combinations of dutasteride and tamsulosin, and mixtures and combinations thereof.
4 . The method of claim 3 , wherein the at least one active agent capable of treating symptoms of, reducing, blocking, inhibiting treating and/or killing unwanted cellular proliferations in mammals is one or more agents selected from the group consisting of tamsulosin, finasteride, terazosin, doxazosin, tadalafil, dutasteride, combinations of dutasteride and tamsulosin, and mixtures and combinations thereof.
5 . The method of claim 1 , wherein the method comprises administration of a therapeutically effective amount of at least one of the peptides as claimed in claim 1 and at least one and up to 25 additional amino acids flanking either the N-terminus or C-terminus of the isolated peptide of claim 1 .
6 . The method of claim 1 , wherein the peptide is administered by a method selected from the group consisting of orally, subcutaneously, intradermally, intranasally, intravenously, intramuscularly, intrathecally, intranasally, intratumorally, topically, and transdermally.
7 . The method of claim 1 , wherein the method is carried out on the mammal before, during, or after treatment of the mammal with a treatment selected from the group consisting of surgical excision, transplantation, grafting, chemotherapy, immunotherapy, vaccination, thermal or electrical ablation, cryotherapy, laser therapy, phototherapy, gene therapy, and radiation.
8 . The method of claim 1 , wherein the condition is a benign or malignant tumor of a tissue selected from the group consisting of lung, breast, stomach, pancreas, prostate, bladder, bone, ovary, skin, kidney, sinus, colon, intestine, stomach, rectum, esophagus, heart, spleen, salivary gland, blood, brain and its coverings, spinal cord and its coverings, muscle, connective tissue, adrenal, parathyroid, thyroid, uterus, testis, pituitary, reproductive organs, liver, gall bladder, eye, ear, nose, throat, tonsils, mouth, and lymph nodes and lymphoid system.
9 . The method of claim 1 , wherein the condition is a hyperplasia, hypertrophy, or overgrowth of a tissue selected from the group consisting of lung, breast, stomach, pancreas, prostate, bladder, bone, ovary, skin, kidney, sinus, colon, intestine, stomach, rectum, esophagus, heart, spleen, salivary gland, blood, brain and its coverings, spinal cord and its coverings, muscle, connective tissue, adrenal, parathyroid, thyroid, uterus, testis, pituitary, reproductive organs, liver, gall bladder, eye, ear, nose, throat, tonsils, mouth, and lymph nodes and lymphoid system.
10 . The method of claim 1 , wherein the condition is a virally, bacterially, or parasitically altered tissue selected from the group consisting of lung, breast, stomach, pancreas, prostate, bladder, bone, ovary, skin, kidney, sinus, colon, intestine, stomach, rectum, esophagus, heart, spleen, salivary gland, blood, brain and its coverings, spinal cord and its coverings, muscle, connective tissue, adrenal, parathyroid, thyroid, uterus, testis, pituitary, reproductive organs, liver, gall bladder, eye, ear, nose, throat, tonsils, mouth, and lymph nodes and lymphoid system.
11 . The method of claim 1 , wherein the condition is a malformation of a tissue selected from the group consisting of lung, breast, stomach, pancreas, prostate, bladder, bone, ovary, skin, kidney, sinus, colon, intestine, stomach, rectum, esophagus, heart, spleen, salivary gland, blood, brain and its coverings, spinal cord and its coverings, muscle, connective tissue, adrenal, parathyroid, thyroid, uterus, testis, pituitary, reproductive organs, liver, gall bladder, eye, ear, nose, throat, tonsils, mouth, and lymph nodes and lymphoid system.
12 . The method of claim 1 , wherein the condition is benign prostatic hyperplasia (BPH).
13 . The method of claim 1 , wherein the method provides a Mean IPSS (International Prostate Symptom Score) improvement, when compared to the improvement found by treating a mammal with a placebo in combination with an additional active agent capable of treating symptoms of, reducing, blocking, inhibiting treating and/or killing unwanted cellular proliferations in mammals, of from about 15% to about 150%.
14 . The method of claim 13 , wherein the improvement is about 40%.
15 . The method of claim 1 , wherein the at least one active agent is administered separately or at different times from the at least one isolated peptide.
16 . The method of claim 15 wherein the at least one isolated peptide is administered by a method selected from the group consisting of intravenously, intramuscularly, intrathecally, intranasally, intratumorally, topically, and transdermally, and the at least one active agent is administered orally.
17 . A method of treating mammal for removal or destruction of unwanted cellular proliferations comprising administering to the mammal a therapeutically effective amount of an isolated peptide comprising the amino acid sequence in SEQ ID NO. 66 (Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-Lys-Leu-Glu-Ile-Lys-Arg-Cys-Leu), followed by surgical treatment of the unwanted cellular proliferations.
18 . The method of claim 17 , wherein the method provides a Mean IPSS (International Prostate Symptom Score) improvement, when compared to the improvement found by treating a mammal with a placebo in combination with surgical treatment of from about 15% to about 150%.